KalVista Pharma

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided multiple clinical trial and regulatory updates for its lead compound sebetralstat, as a potential oral on-demand therapy for HAE attacks.

KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks has been published in the international weekly medical journal, The Lancet.

KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet

KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thursday, February 16, 2023 at 8:40 a.m. ET.

KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. The backbone of the company is Sebetralstat, which is currently being investigated in a phase 3 trial for the on-demand treatment of HAE attacks - a potentially billion-dollar market opportunity.

KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis

CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the promotion of Ben Palleiko, the Company's current Chief Business Officer and Chief Financial Officer, to the additional title of President. In this expanded role, Mr. Palleiko will be responsible for leading broadly the Company's future business growth, including development of the commercial organization for the intended worldwide launch of sebetralstat, currently in Phase 3 clinical development as the first potential oral, on-demand treatment for hereditary angioedema (HAE) attacks.

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sell, in a registered direct offering, an aggregate of 9.484 million shares of common stock at a price of $6.00 per share and 182,470 prefunded warrants at a price of $5.999 for total gross proceeds of approximately $58 million, before deducting estimated offering expenses. The offering is expected to close on December 28, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds of this $58 million offering to fund clinical trials, commercial sales development, research, working capital, capital expenditures and other general corporate purposes. With the financing, combined with the Company's existing cash balance and anticipated receipts as of October 31, 2022, KalVista now expects to be able to fund operations into 2025.

KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

Achieve Life Sciences

Amprius Technologies Inc

Bilibili

Champions Oncology

Digimarc

Gannett Co.

KLX Energy Services Holdings Inc

System1, Inc

Unity Biotechnology Inc

With the significant volatility and uncertainty in equity markets expected to continue through 2023, some investors are seeking alternative short to medium-term trading ideas.

Fintel's top 10 Gamma Squeeze Stocks For November

CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented two posters at the 2022 meeting of the American College of Allergy, Asthma & Immunology in Louisville, Kentucky. The first highlighted new data that reveals the significant impact of HAE attacks on the mental health, daily activities, and quality of life for people living with hereditary angioedema (HAE) receiving either parenterally delivered on-demand only treatment or prophylaxis with on-demand treatment for breakthrough attacks. More than half of people with HAE felt unable to participate in important events or activities, while nearly half felt ‘less than 100% themselves' due to HAE.

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D.

KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the second half of 2023.

KalVista: Another Setback But The Key Value Driver Is Still In Place

NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether KalVista the Runway and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented new data on patient-preferred on-demand treatment measures in hereditary angioedema (HAE), and on the effects that the disease has on quality of life for people living with HAE, at the 2022 HAEi Global Leadership Workshop in Frankfurt

KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

KalVista (KALV) Stock Continues to Decline: Here's Why

Kalvista Pharmaceuticals scrapped an experimental hereditary angioedema drug on Tuesday due to safety issues, and the biotech stock tumbled.  The post Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap appeared first on Investor's Business Daily.

Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap

KalVista Pharmaceuticals (NASDAQ: KALV ) is trending on popular financial social media right now, but it's not good news. Reportedly, there were safety-related concerns over KalVista's clinical study of a hereditary angioedema treatment.

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?

News for KalVista Pharma Stock (KALV)